These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30101540)

  • 41. Theranostic Upconversion Nanobeacons for Tumor mRNA Ratiometric Fluorescence Detection and Imaging-Monitored Drug Delivery.
    Ding Q; Zhan Q; Zhou X; Zhang T; Xing D
    Small; 2016 Nov; 12(43):5944-5953. PubMed ID: 27647762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Research advances in integrated theranostic probes for tumor fluorescence visualization and treatment.
    Xing J; Gong Q; Akakuru OU; Liu C; Zou R; Wu A
    Nanoscale; 2020 Dec; 12(48):24311-24330. PubMed ID: 33300527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nano-lipospheres as acoustically active ultrasound contrast agents: evolving tumor imaging and therapy technique.
    Andrews LE; Chan MH; Liu RS
    Nanotechnology; 2019 May; 30(18):182001. PubMed ID: 30645984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.
    Conde J; Oliva N; Artzi N
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1278-87. PubMed ID: 25733851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds.
    Buller F; Steiner M; Frey K; Mircsof D; Scheuermann J; Kalisch M; Buhlmann P; Supuran CT; Neri D
    ACS Chem Biol; 2011 Apr; 6(4):336-44. PubMed ID: 21186831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The application of nanoparticles in diagnosis and theranostics of gastric cancer.
    Li R; Liu B; Gao J
    Cancer Lett; 2017 Feb; 386():123-130. PubMed ID: 27845158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging.
    Kong F; Liang Z; Luan D; Liu X; Xu K; Tang B
    Anal Chem; 2016 Jun; 88(12):6450-6. PubMed ID: 27216623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanoscale theranostics for physical stimulus-responsive cancer therapies.
    Chen Q; Ke H; Dai Z; Liu Z
    Biomaterials; 2015 Dec; 73():214-30. PubMed ID: 26410788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy--
AKT/m-TOR Pathway and Resistance to Cancer Therapy.
    Spirina LV; Kondakova IV; Tarasenko NV; Slonimskaya EM; Usynin EA; Gorbunov AK; Yurmazov ZA; Chigevskaya SY
    Zhongguo Fei Ai Za Zhi; 2018 Jan; 21(1):63-66. PubMed ID: 29357975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual-stimuli responsive theranostic agents based on small molecules.
    Xue SS; Zhu W; Li Y; Pan W; Li N; Tang B
    Chem Commun (Camb); 2024 Sep; 60(73):9860-9870. PubMed ID: 39157895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor.
    Avvakumova S; Galbiati E; Sironi L; Locarno SA; Gambini L; Macchi C; Pandolfi L; Ruscica M; Magni P; Collini M; Colombo M; Corsi F; Chirico G; Romeo S; Prosperi D
    Bioconjug Chem; 2016 Dec; 27(12):2911-2922. PubMed ID: 27809498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.
    Chen F; Hong H; Goel S; Graves SA; Orbay H; Ehlerding EB; Shi S; Theuer CP; Nickles RJ; Cai W
    ACS Nano; 2015; 9(4):3926-34. PubMed ID: 25843647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer.
    Vandghanooni S; Eskandani M; Barar J; Omidi Y
    Eur J Pharm Sci; 2018 May; 117():301-312. PubMed ID: 29499349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disulfide-based multifunctional conjugates for targeted theranostic drug delivery.
    Lee MH; Sessler JL; Kim JS
    Acc Chem Res; 2015 Nov; 48(11):2935-46. PubMed ID: 26513450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A bimodal fluorescent and photocytotoxic naphthalene diimide for theranostic applications.
    Salvati E; Doria F; Manoli F; D'Angelo C; Biroccio A; Freccero M; Manet I
    Org Biomol Chem; 2016 Jul; 14(30):7238-49. PubMed ID: 27383473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy.
    Yang H; Shen X; Yan J; Xie X; Chen Z; Li T; Li S; Qin X; Wu C; Liu Y
    Biomater Sci; 2018 Aug; 6(9):2426-2439. PubMed ID: 30040100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
    Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
    Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.
    Lategahn J; Keul M; Rauh D
    Angew Chem Int Ed Engl; 2018 Feb; 57(9):2307-2313. PubMed ID: 29178586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.